BB 76163
Latest Information Update: 01 Aug 2001
At a glance
- Originator British Biotech
- Class
- Mechanism of Action Aminopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 01 Aug 2001 Discontinued-Preclinical for Multiple sclerosis in United Kingdom (Unknown route)
- 06 Nov 2000 Serono has gained rights to BB 76163
- 02 Aug 2000 New profile